Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05541471 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT05541471 is a Phase 1 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 37 participants.
The verdict
NCT05541471, a Phase 1 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetics of midazolam and digoxin in the absence and presence of VX-548.
Interventions
- DRUG Midazolam
- DRUG Digoxin
- DRUG VX-548
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2022-09-22 |
| Est. Completion | 2023-04-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05541471
The ClinicalTrials.gov registry entry for NCT05541471 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Midazolam is the first listed.
NCT05541471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05541471 about?
NCT05541471 is a clinical study titled "A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin". The purpose of this study is to evaluate the pharmacokinetics of midazolam and digoxin in the absence and presence of VX-548.
What is the current status of trial NCT05541471?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2022-09-22. Estimated completion is 2023-04-28.
What interventions are being tested in trial NCT05541471?
The interventions under investigation include: Midazolam (DRUG), Digoxin (DRUG), VX-548 (DRUG).
Who is sponsoring clinical trial NCT05541471?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.